Personal information

Verified email domains

Biography

My scientific interest is in genetic and epigenetic mechanisms underlying brain tumors, with a particular focus on translation of molecular insights into improved patient care. Beginning as a graduate student, I have sought to understand the relationship of specific genomic alterations with clinical phenotypes, including prognosis and response to targeted chemotherapies. I hope to leverage discoveries regarding the formation and progression of brain tumors into improved clinical management, such as identification of tractable biomarkers, as well as precision medicines that exploit epigenetic vulnerabilities. My graduate work focused primarily on meningiomas, the most common primary brain tumor, and a disease for which invasive and risky neurosurgical procedures remain the primary treatment. Using integrated approaches, our team identified new genomic and epigenetic mechanisms involved in the formation of approximately one-third of these lesions, as well as important pathways that underlie progression of low-grade to high-grade tumors. This work was partially funded by an NIH F30 grant that I received for three years, and resulted in several publications that are discussed below. Since graduating medical school in 2019, I am currently training as a neurosurgery resident at Northwestern, and continue to work closely with new collaborators on the study of brain tumors. Based on close collaborations between basic scientists, neurosurgeons, neuro-oncologists at our institution, as well as a large population of brain tumor patients in our health care system, we are well-poised for rapid translation of new insights into improved patient care.

Activities

Employment (1)

Intel Corporation: Santa Clara, CA, US

2008-01-01 to 2010-08-01 | Microprocessor Design Engineer
Employment
Source: Self-asserted source
Mark W. Youngblood

Education and qualifications (3)

Northwestern Memorial Hospital: Chicago, IL, US

2019-07-01 to present | Resident (Neurosurgery)
Qualification
Source: Self-asserted source
Mark W. Youngblood

Yale School of Medicine: New Haven, CT, US

2012-08-01 to 2019-05-01 | Doctor of Philosophy (Genetics)
Education
Source: Self-asserted source
Mark W. Youngblood

Yale School of Medicine: New Haven, CT, US

2012-08-01 to 2019-05-01 | Doctor of Medicine
Education
Source: Self-asserted source
Mark W. Youngblood

Professional activities (5)

Society for Neuro-Oncology: Houston, TX, US

Membership
Source: Self-asserted source
Mark W. Youngblood

Congress of Neurological Surgeons: Schaumburg, IL, US

Membership
Source: Self-asserted source
Mark W. Youngblood

American Association of Neurological Surgeons: Rolling Meadows, Illinois, US

Membership
Source: Self-asserted source
Mark W. Youngblood

Congress of Neurological Surgeons: Schaumburg, IL, US

2022-10-29 | Best Basic Science Poster (Tumor)
Distinction
Source: Self-asserted source
Mark W. Youngblood

American Association of Neurological Surgeons: Rolling Meadows, Illinois, US

2017-04-01 | Integra Foundation Award for Brain Tumor Research
Distinction
Source: Self-asserted source
Mark W. Youngblood

Funding (5)

Evaluating STING as a Therapeutic Approach in Meningiomas

2024-07 to 2025-07 | Grant
Society of Neurological Surgeons (Schaumburg, Illinois, US)
Source: Self-asserted source
Mark W. Youngblood

Predicting Glioblastoma Response to Paclitaxel and Carboplatin After Opening the Blood-Brain Barrier

2024-04-15 to 2026-04-14 | Grant
Congressionally Directed Medical Research Programs (Frederick, US)
GRANT_NUMBER:

HT9425-24-1-0313

Source: Self-asserted source
Mark W. Youngblood via DimensionsWizard

Molecular Markers of Meningioma Growth Arrest After HDAC Inhibition

2022-07 to 2023-06 | Grant
Neurosurgery Research and Education Foundation (IL, IL, US)
Source: Self-asserted source
Mark W. Youngblood

Transcriptional Drivers of Aggressive Behavior in Meningiomas

2022-03 to 2023-03 | Grant
Malnati Brain Tumor Institute (Chicago, IL, US)
Source: Self-asserted source
Mark W. Youngblood

PBAF Signaling in Meningioma Tumorigenesis

2018-02-01 to 2019-05-31 | Grant
National Cancer Institute (Bethesda, US)
GRANT_NUMBER: F30CA213666
Source: Self-asserted source
Mark W. Youngblood via DimensionsWizard